Commentary| Volume 60, ISSUE 1, P73-74, January 2007

Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II

  • Ardeshir Bayat
    Corresponding author. Tel.: +44 7940 090176; fax: +44 161 2751617.
    Department of Plastic and Reconstructive Surgery, South Manchester University Hospital Trust, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK
    Search for articles by this author
      Hypertrophic scars (HSs) can cause significant aesthetic and functional symptoms and to-date no optimal treatment has been established. Many causes have been associated with HS development but regardless, it presents with appearance of myofibroblasts and an abnormal deposition of extracellular matrix (ECM) collagens. This accumulation makes ECM a logical target for pharmacological interventions, and researchers are endeavouring to modify ECM metabolism.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Liu W.
        • Wang D.R.
        • Cao Y.L.
        TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy.
        Curr Gene Ther. 2004; 4: 123-136
        • Bock O.
        • Yu H.
        • Zitron S.
        • et al.
        Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
        Acta Derm Venereol. 2005; 85: 216-220
        • Reid R.R.
        • Roy N.
        • Mogford J.E.
        • et al.
        Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II.
        J Plast Reconstr Aesth Surg. 2006; 59: 64-72
        • Liu W.
        • Chua C.
        • Wu X.
        • et al.
        Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II.
        Plast Reconstr Surg. 2005; 115: 860-870
        • Nakamuta M.
        • Morizono S.
        • Tsuruta S.
        • et al.
        Remote delivery and expression of soluble type II TGF-beta receptor in muscle prevents hepatic fibrosis in rats.
        Int J Mol Med. 2005; 16: 59-64
        • Forrester E.
        • Chytil A.
        • Bierie B.
        • et al.
        Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
        Cancer Res. 2005; 65: 2296-2302
        • Gorska A.E.
        • Jensen R.A.
        • Shyr Yu
        • et al.
        Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation.
        Am J Pathol. 2003; 163: 1539-1549

      Linked Article

      • Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-β receptor II
        Journal of Plastic, Reconstructive & Aesthetic SurgeryVol. 60Issue 1
        • Preview
          Effective blockade of the pluripotent cytokine transforming growth factor (TGF)-β as a means of cutaneous scar reduction is a strategy with great potential. This desired effect may be achieved through the overexpression of mutant TGF-β receptors within the wound milieu. Our goal was to examine the effects of dominant negative mutant TGF-β receptor II (TGFβRIIdn) protein expression in a well-established rabbit ear model of hypertrophic scarring. Serial injections of a retroviral construct encoding a truncated TGFβRII and the marker green fusion protein (pMSCV-rIIdn-GFP) were performed in 7 mm punch wounds at day 10 and day 12 (two-day injection group) or days 8, 10, 12 (three-day injection group) post-wounding.
        • Full-Text
        • PDF